JAMA Network Home
Sign In
Research Letter

Cancer Risk Concerns and Communication Gaps Regarding GLP-1 Medications

JAMA Network Open 10.1001/jamanetworkopen.2025.21878

July 18, 2025 at 11:00 AM EDT

Read the full article

This cross-sectional study analyzes social media posts to explore patient concerns and the extent of patient–clinician communication regarding cancer risks associated with glucagon-like peptide-1 (GLP-1) medications.

Corresponding Author: Osama Mohamad, MD, PhD, Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1050, Houston, TX 77030 (omohamad@mdanderson.org).

Link to the article in your story

We encourage you to link out to this article in your your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.21878?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=071825

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks